Efficacy according to cohort and subtype
| Cohorts . | Total treated . | Total evaluable for response . | ORR . | CBR . | CR . | PR . | SD >6 mo . |
|---|---|---|---|---|---|---|---|
| Cohort 1 | 21 | 21 | 7 (33%) | 10 (48%) | 1 (5%) | 6 (29%) | 3 (14%) |
| Cohort 2 | 15 | 14 | 4 (29%) | 5 (36%) | 2 (14%) | 2 (14%) | 1 (7%) |
| Cohort 3 | 17 | 17 | 2 (12%) | 3 (18%) | 0 | 2 (12%) | 1 (6%) |
| Total | 53 | 52 | 13 (25%) | 18 (35%) | 3 (6%) | 10 (19%) | 5 (10%) |
| P (cohorts 1 & 2 vs 3) | P = .2 | P = .073 | |||||
| Cohorts . | Total treated . | Total evaluable for response . | ORR . | CBR . | CR . | PR . | SD >6 mo . |
|---|---|---|---|---|---|---|---|
| Cohort 1 | 21 | 21 | 7 (33%) | 10 (48%) | 1 (5%) | 6 (29%) | 3 (14%) |
| Cohort 2 | 15 | 14 | 4 (29%) | 5 (36%) | 2 (14%) | 2 (14%) | 1 (7%) |
| Cohort 3 | 17 | 17 | 2 (12%) | 3 (18%) | 0 | 2 (12%) | 1 (6%) |
| Total | 53 | 52 | 13 (25%) | 18 (35%) | 3 (6%) | 10 (19%) | 5 (10%) |
| P (cohorts 1 & 2 vs 3) | P = .2 | P = .073 | |||||
| Subtypes . | Total treated . | Total evaluable for response . | ORR . | CBR . | CR . | PR . | SD >6 mo . |
|---|---|---|---|---|---|---|---|
| PTCL, NOS | 12 | 11 | 2 (18%) | 2 (18%) | 1 (9%) | 1 (9%) | 0 |
| T-PLL | 8 | 8 | 3 (38%) | 4 (50%) | 0 | 3 (38%) | 1 (13%) |
| AITL/TFH | 9 | 9 | 3 (33%) | 4 (44%) | 1 (11%) | 2 (22%) | 1 (11%) |
| T-LGL | 5 | 5 | 2 (40%) | 4 (80%) | 0 | 2 (40%) | 2 (40%) |
| ALCL | 4 | 4 | 1 (25%) | 1 (25%) | 1 (25%) | 0 | 0 |
| ATLL | 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| MF | 7 | 7 | 1 (14%) | 1 (14%) | 0 | 1 (14%) | 0 |
| γ/δ TCLs | 4 | 4 | 1 (25%) | 1 (25%) | 0 | 1 (25%) | 0 (0%) |
| SPTCL | 1 | 1 | 0 | 1 (100%) | 0 | 0 | 1(100%) |
| Subtypes . | Total treated . | Total evaluable for response . | ORR . | CBR . | CR . | PR . | SD >6 mo . |
|---|---|---|---|---|---|---|---|
| PTCL, NOS | 12 | 11 | 2 (18%) | 2 (18%) | 1 (9%) | 1 (9%) | 0 |
| T-PLL | 8 | 8 | 3 (38%) | 4 (50%) | 0 | 3 (38%) | 1 (13%) |
| AITL/TFH | 9 | 9 | 3 (33%) | 4 (44%) | 1 (11%) | 2 (22%) | 1 (11%) |
| T-LGL | 5 | 5 | 2 (40%) | 4 (80%) | 0 | 2 (40%) | 2 (40%) |
| ALCL | 4 | 4 | 1 (25%) | 1 (25%) | 1 (25%) | 0 | 0 |
| ATLL | 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| MF | 7 | 7 | 1 (14%) | 1 (14%) | 0 | 1 (14%) | 0 |
| γ/δ TCLs | 4 | 4 | 1 (25%) | 1 (25%) | 0 | 1 (25%) | 0 (0%) |
| SPTCL | 1 | 1 | 0 | 1 (100%) | 0 | 0 | 1(100%) |
AITL/TFH, angioimmunoblastic T-cell lymphoma and other T-follicular helper lymphomas; ATLL, adult T-cell lymphoma lymphoma/leukemia; γ/δ TCL, γ/δ T-cell lymphomas; SPTCL, subcutaneous panniculitis-like T-cell lymphoma.